TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15970103

Group type: EXPERIMENTAL
Intervention: Verapamil-procaine compound (V-P)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Procaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (only glucose)
Number of subjects: 150
Study: 12575474

Group type: EXPERIMENTAL
Intervention: 2 mg of citalopram
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 800 mg S-adenosyl-L-methionine (SAMe) administered intravenously
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard ERP components
Number of subjects: 60
Study: 10597810

Group type: EXPERIMENTAL
Intervention: Bilateral injections of 2% lidocaine solution without epinephrine into the paraglottic space containing the ibSLN
Number of subjects: 9
Study: 8589027

Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 administered intravenously by 30‐minute infusion for 5 days
Number of subjects: 57
Study: 2144743

Group type: EXPERIMENTAL
Intervention: Azlocillin plus a long course (at least 9 days) of amikacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftazidime plus a short course (3 days) of amikacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus a long course of amikacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azlocillin plus amikacin in patients with prolonged and severe neutropenia
Number of subjects: 0
Study: 273801

Group type: EXPERIMENTAL
Intervention: ALICE live virus intra-nasal vaccine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sub-unit vaccine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo intra-nasal vaccine
Number of subjects: 157
Study: 31387390

Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy intervention (50-min session per week for 9 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 31303298

Group type: EXPERIMENTAL
Intervention: Family planning intervention package (refresher training for providers, counselling tool, supportive supervision, availability of contraceptive services 7 days a week, client appointment cards, invitation letters for partners)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Family planning intervention package
Number of subjects: 571
Study: 27696447

Group type: EXPERIMENTAL
Intervention: INCS on demand (fluticasone propionate)
Number of subjects: 150

Group type: COMPARATOR
Intervention: INCS daily (fluticasone propionate)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oral antihistamine on demand (levocetirizine)
Number of subjects: 150
Study: 26155819

Group type: EXPERIMENTAL
Intervention: IMPLEMENT intervention (two-session interactive workshop with didactic presentations and small group discussions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 0
Study: 23441978

Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg bid for 21 days with artemether/lumefantrine 80/480 mg from day 8 (3-day course)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 600/100 mg bid with artemether/lumefantrine 80/480 mg (3-day course)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Artemether/lumefantrine
Number of subjects: 33
Study: 21502557

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy with cisplatin, methotrexate, and vinblastine (CMV), 3 cycles.
Number of subjects: 976

Group type: COMPARATOR
Intervention: No neoadjuvant chemotherapy (Control).
Number of subjects: 976
Study: 19656815

Group type: EXPERIMENTAL
Intervention: Motor control training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endurance/strength training
Number of subjects: 25
Study: 16708161

Group type: EXPERIMENTAL
Intervention: Red hot chili pepper
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15056388

Group type: EXPERIMENTAL
Intervention: Vasectomy with fascial interposition
Number of subjects: 841

Group type: COMPARATOR
Intervention: Vasectomy without fascial interposition
Number of subjects: 841
Study: 11563428

Group type: EXPERIMENTAL
Intervention: Hand-held OBF tonometer
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Slit-lamp mounted OBF tonometer
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both methods of application
Number of subjects: 35
Study: 9029858

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Number of subjects: 16
Study: 8124440

Group type: EXPERIMENTAL
Intervention: Functional brace (the Galveston metacarpal brace)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Dorsal/ulnar plaster cast
Number of subjects: 133
Study: 3314613

Group type: EXPERIMENTAL
Intervention: Oral diltiazem 120 to 180 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29516704

Group type: EXPERIMENTAL
Intervention: 0.5 mcg/kg/h dexmedetomidine in addition to half dose of opioids and benzodiazepines (D-CASEs)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard dose opioids and benzodiazepines (CONTROLs)
Number of subjects: 48
Study: 27070409

Group type: COMPARATOR
Intervention: Neuroplasticity-based training program for sensory signal-to-noise resolution, 30 hours over 6 months.
Number of subjects: 0
Study: 25271627

Group type: EXPERIMENTAL
Intervention: NYVAC/Ad5hi
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ad5lo/NYVAC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ad5med/NYVAC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ad5hi/NYVAC
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23103475

Group type: EXPERIMENTAL
Intervention: Coronary Artery RIsk MAnagement Programme (CARIMAP)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 168
Study: 20859892

Group type: EXPERIMENTAL
Intervention: Intravenous hydration with isotonic solution (0.9% NaCl)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Oral hydration with mineral water
Number of subjects: 102
Study: 18098171

Group type: EXPERIMENTAL
Intervention: Angio-Seal VIP
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Perclose Proglide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Compression
Number of subjects: 200
Study: 16647616

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring
Number of subjects: 98

Group type: COMPARATOR
Intervention: Home blood pressure monitoring
Number of subjects: 98
Study: 12844139

Group type: EXPERIMENTAL
Intervention: Anakinra (1 mg/kg) administered intravenously to healthy subjects
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anakinra (1 mg/kg) administered intravenously to subjects with end-stage renal disease
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with normal renal function
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with mildly impaired renal function
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with moderately impaired renal function
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with severely impaired renal function
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with end-stage renal disease
Number of subjects: 62

Group type: COMPARATOR
Intervention: Dialysis effect on anakinra clearance
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Correlation between anakinra CL/F and CL(cr)
Number of subjects: 62
Study: 10718513

Group type: EXPERIMENTAL
Intervention: Physostigmine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infusion of saline
Number of subjects: 0
Study: 8667466

Group type: EXPERIMENTAL
Intervention: Loading dose followed by continuous infusion of pralidoxime (16 mg/kg over 30 minutes)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Short infusion regimen of pralidoxime (4 mg/kg over 15 minutes followed by 3.2 mg/kg/h for 3.75 h)
Number of subjects: 7
Study: 1642486

Group type: EXPERIMENTAL
Intervention: Efficacy enhancement nursing care group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 156
Study: 6869711

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 0.2 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 0.4 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Buffered placebo
Number of subjects: 60
Study: 31420191

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6245
Study: 29699527

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (active arm of the InterACT trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27171331

Group type: EXPERIMENTAL
Intervention: EMR + RFA
Number of subjects: 0

Group type: COMPARATOR
Intervention: SRER
Number of subjects: 0
Study: 24084496

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Monthly dosing
Number of subjects: 1024

Group type: COMPARATOR
Intervention: PRN dosing
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Baseline visual acuity (VA) ≤20/200
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Retinal angiomatous proliferation (RAP)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: GA in the fellow eye
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Intraretinal fluid at the foveal center
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Blocked fluorescence
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: OCT measurements of subretinal fluid thickness >25 μ
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Subretinal tissue complex thickness >275 μ compared with ≤75 μ
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Vitreomacular attachment
Number of subjects: 1024
Study: 22764542

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine without a vasoconstrictor
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% lidocaine with adrenaline (1 : 80.000)
Number of subjects: 60
Study: 19106673

Group type: EXPERIMENTAL
Intervention: TEP (totally extraperitoneal patch)
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 1512
Study: 17489035

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 561

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 561
Study: 15597171

Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 48
Study: 11594447

Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg twice daily for 14 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9870876

Group type: EXPERIMENTAL
Intervention: IL‐1Ra 150 mg/day
Number of subjects: 472

Group type: COMPARATOR
Intervention: IL‐1Ra
Number of subjects: 472
Study: 7672875

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin equivalent to 20 mg piroxicam
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 2659737

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 x 10(6) units)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Transfer factor (0.5 units)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 29362260

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention targeting health-promoting policies and practices in junior sporting clubs.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study: 28222815

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 34
Study: 25627448

Group type: EXPERIMENTAL
Intervention: LDV/SOF (8 weeks)
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: LDV/SOF (12 weeks)
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: LDV/SOF (24 weeks)
Number of subjects: 1952

Group type: COMPARATOR
Intervention: LDV/SOF+RBV (all durations)
Number of subjects: 1952

Group type: EXPERIMENTAL
Intervention: Sustained virological response at 12 weeks
Number of subjects: 1952
Study: 22914584

Group type: EXPERIMENTAL
Intervention: Primary immunization with recombinant hepatitis B vaccine
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Primary immunization with recombinant hepatitis B vaccine (Group 1, 5 years post-vaccination)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Primary immunization with recombinant hepatitis B vaccine (Group 2, 10 years post-vaccination)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Primary immunization with recombinant hepatitis B vaccine (Group 3, 15 years post-vaccination)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Booster dose of hepatitis B vaccine
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Booster dose of hepatitis B vaccine (administered to children with anti-HBs <10 mIU/mL)
Number of subjects: 141
Study: 20683930

Group type: EXPERIMENTAL
Intervention: Colesevelam (1875 mg twice daily for 3 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (identical to colesevelam, twice daily for 3 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18000709

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg plus dexamethasone 8 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Intralipid)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg combined with dexamethasone 8 mg
Number of subjects: 120
Study: 16563558

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m² on days 1 and 8) and Nedaplatin (100 mg/m² on day 1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Nedaplatin
Number of subjects: 34
Study: 14578911

Group type: EXPERIMENTAL
Intervention: BILN 2061, a small molecule NS3 protease inhibitor administered orally for 2 days
Number of subjects: 0
Study: 10985991

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 260
Study: 9011484

Group type: EXPERIMENTAL
Intervention: IFN 3 MU three times a week for six months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IFN 6 MU three times a week for six months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IFN 3 MU three times a week for 12 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IFN 6 MU three times a week for 12 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IFN 3 MU three times a week for up to 18 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 33
Study: 1730124

Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of radioactive phosphorus (32P)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2)
Number of subjects: 347

Group type: COMPARATOR
Intervention: 32P
Number of subjects: 347

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 347
Study: 4061965

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (sustained-release form)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 0
Study: 29895931

Group type: EXPERIMENTAL
Intervention: Fixed-dose (FD) plerixafor 20 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Weight-based (WB) plerixafor 0.24 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both FD and WB groups
Number of subjects: 61
Study: 29880728

Group type: EXPERIMENTAL
Intervention: Protaetia brevitarsis seulensis Kolbe, 1886 (PB) extract
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oxya chinensis sinuosa Mishchenko, 1951 (OC) extract
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Gryllus bimaculatus De Geer, 1773 (GB) extract
Number of subjects: 3
Study: 26310871

Group type: EXPERIMENTAL
Intervention: CHOICES (Web-based multimedia education program)
Number of subjects: 234

Group type: COMPARATOR
Intervention: e-Book (usual care education)
Number of subjects: 234
Study: 24359044

Group type: EXPERIMENTAL
Intervention: 50 mg of intravenous dexketoprofen trometamol via slow i.v. infusion (Group I)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 1,000 mg of paracetamol via intravenous infusion (Group II)
Number of subjects: 82
Study: 22418981

Group type: EXPERIMENTAL
Intervention: Higher dietary sodium intake
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Sodium to calorie intake ratio
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: Sodium to potassium ratio
Number of subjects: 1770

Group type: COMPARATOR
Intervention: Prescribed dietary sodium restriction
Number of subjects: 1770
Study: 20724934

Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 108
Study: 18757354

Group type: EXPERIMENTAL
Intervention: SunWise Policy plus Technical Assistance
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (EPA's original SunWise curriculum toolkit)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SunWise Policy (revised toolkit emphasizing policy)
Number of subjects: 28
Study: 15309331

Group type: EXPERIMENTAL
Intervention: Exercise or pharmacological stress testing with (99m)Tc-sestamibi, 201Tl or both
Number of subjects: 133
Study: 12122552

Group type: EXPERIMENTAL
Intervention: 25 g isomalt
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 25 g lycasin HBC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 40 g lycasin HBC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 40 g isomalt
Number of subjects: 51
Study: 10380982

Group type: EXPERIMENTAL
Intervention: Single feature conditions (color or orientation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjunction targets (both color and orientation)
Number of subjects: 0
Study: 8531615

Group type: EXPERIMENTAL
Intervention: Two-parameter nonlinear model
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Three-parameter nonlinear model
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Linear (P.t) model
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Linear (P) model
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exponential model
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ventilatory threshold for long-term exercise (LTE Tvent)
Number of subjects: 16
Study: 1693733

Group type: EXPERIMENTAL
Intervention: Felodipine ER tablets 10 mg once daily (n = 50)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Plain tablets 5 mg twice daily (n = 52)
Number of subjects: 102
Study: 582722

Group type: EXPERIMENTAL
Intervention: i.v. cefazedone 500 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: i.v. cefazedone 1000 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: i.m. cefazedone 500 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: cefazolin 1000 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: cefazolin 500 mg
Number of subjects: 10
Study: 30413390

Group type: EXPERIMENTAL
Intervention: Catheter removal on postoperative day 3 (POD 3)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Catheter removal on postoperative day 5 (POD 5)
Number of subjects: 146
Study: 31113763

Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Standard guidance
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 1388
Study: 29167518

Group type: EXPERIMENTAL
Intervention: Increased theta activity during menstrual phase
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Increased theta activity during periovulatory phase
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlations between theta activity and psychological measures
Number of subjects: 46
Study: 26690199

Group type: EXPERIMENTAL
Intervention: rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF)
Number of subjects: 151

Group type: COMPARATOR
Intervention: efavirenz (EFV)/FTC/TDF
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: baseline HIV-1 RNA >100,000 copies/mL
Number of subjects: 151

Group type: COMPARATOR
Intervention: baseline samples from control subjects
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: deep sequencing
Number of subjects: 151
Study: 24124672

Group type: EXPERIMENTAL
Intervention: CTEPH group
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CTEPH and CPE groups
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: NT‐proBNP
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Right ventricular internal diameter and VO2/kg
Number of subjects: 116
Study: 21147813

Group type: EXPERIMENTAL
Intervention: Relaxation training according to Yoga In Daily Life(®) system
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 32
Study: 18310964

Group type: EXPERIMENTAL
Intervention: delapril 30 mg/manidipine 10 mg combination
Number of subjects: 88

Group type: COMPARATOR
Intervention: olmesartan 20 mg/HCTZ 12.5 mg combination
Number of subjects: 88
Study: 17518172

Group type: EXPERIMENTAL
Intervention: Continuous infusion of remifentanil plus morphine and nonsteroidal anti-inflammatory drugs
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bolus doses of fentanyl
Number of subjects: 29
Study: 12920414

Group type: EXPERIMENTAL
Intervention: Trazodone (TRZ)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study: 10998766

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program
Number of subjects: 235

Group type: COMPARATOR
Intervention: Structured exercise program
Number of subjects: 235
Study: 9384327

Group type: EXPERIMENTAL
Intervention: Dermagraft, a tissue-engineered living human dermal tissue; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 1562861

Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 0